Neuropeptide Y induced attenuation of catecholamine synthesis in the rat mesenteric arterial bed

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 6, 2006, Pages 723-728

  Westfall, Thomas C ^a   Naes, Linda ^a   Gardner, Alice ^a   Yang, Chun Lian ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Catecholamine; DOPA; Nesenteric artery; Neuropeptide Y; Norepinephrine; Typrosine hydroxylation

Indexed keywords

1 NAPHTHALENESULFONIC ACID [4 [(4 AMINO 2 QUINAZOLINYLAMINO)METHYL] CYCLOHEXYLMETHYL]AMIDE; 3 HYDROXYBENZYLHYDRAZINE; DECARBOXYLASE INHIBITOR; DOPA; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; N2 DIPHENYLACETYL N (4 UREIDOMETHYLBENZYL)ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NORADRENALIN; PANCREAS POLYPEPTIDE; PEPTIDE DERIVATIVE; PEPTIDE YY; PEPTIDE YY[13-36]; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTERY PERFUSION; ARTICLE; CATECHOLAMINE SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; HYDROXYLATION; IC 50; MESENTERIC ARTERY; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT;

ANIMALS; CATECHOLAMINES; DIHYDROXYPHENYLALANINE; DOPA DECARBOXYLASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; HYDRAZINES; HYDROXYLATION; MALE; MESENTERIC ARTERIES; NEUROPEPTIDE Y; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROPEPTIDE Y; TYROSINE;

EID: 33748110282     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000211761.06271.15     Document Type: Article

References (35)

1. Wahlestedt C, Reis DJ. Neuropeptide Y-related peptides and their receptors - are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxicol. 1993;32:309-352.
2. Grundemar L. Multiple Receptors and Multiple Actions in Neuropeptide Y and Drug Development. In: Grundemar L, Bloom S, eds. Academic Press; 1997;1-14.
3. Westfall TC, Carpentier S, Chen X, et al. Prejunctional and postjunctional effects of neuropeptide Y at the noradrenergic neuroeffector junction of the perfused mesenteric arterial bed of the rat. J Cardiovas Pharmacol. 1987;10:716-722.
4. Westfall TC, Chen X, Ciarleglio A, et al. In vitro effects of neuropepide Y at the vascular neuroeffector junction. Ann NY Acad Sci. 1990;611:145-155.
5. Oellerich WF, Schwartz DD, Malik IU. Neuropeptide Y inhibits adrenergic transmitter release in cultured rat superior cervical ganglion cells by restricting the availability of calcium through a pertussis toxin-sensitive mechanism. Neuroscience. 1994;60:495-502.
6. Chen X, Westfall TC. Modulation of intracellular calcium transients and dopamine release by neuropeptide Y in PC-12 cells. Am J Physiol. 1994;266(Cell Physiol. 35):C784-C793.
7. DiMaggio DA, Farah JM, Westfall TC. Effects of differentiation on neuropeptide-Y receptors and responses in rat pheochromocytoma cells. Endocrinology. 1994;134:719-727.
8. Bitran M, Tapia W, Eugenin E, et al. Neuropeptide Y induced inhibition of noradrenaline release in rat hypothalamus: role of receptor subtype and nitric oxide. Brain Res. 1999;851:87-93.
9. McCullough LA, Westfall TC. Neuropeptide Y inhibits depolarization- stimulated catecholamine synthesis in rat pheochromocytoma cells. Eur J Pharmacol. 1995;287:271-277.
10. 2+ channels and protein kinases. J Neurochem. 1996;67:1090-1099.
11. McCullough LA, Egan TM, Westfall TC. Neuropeptide Y inhibition of calcium currents in PC-12 pheochromocytoma cells. Amer J Physiol. 1998a;274(Cell Physiol. 43):C1290-C1297.
12. 2 receptor antagonist. Br J Pharmacol. 2000a;129:1025-1088.
13. 1) and CGP71683A (Y). Can J Phys Pharm. 2000b;78:116-125.
14. 1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol. 1998;125:549-555.
15. 2 receptor antagonist. Eur J Pharmacol. 1999;384:R3-R5.
16. Galloway MP, Wolf ME, Roth RH. Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: Studies in vivo. J Pharm Exp Ther. 1986;236:689-698.
17. Clark D, Salah RS, Galloway MP. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: dependence on extracellular dopamine. Synapse. 1991;8:69-176.
18. Harada K, Miller E, Goldstein M. Effects of peruses toxin on inhibition of synaptosomal tyrosine hydroxylase activity by apomorphine. Eur J Pharmacol. 1990;188:123-128.
19. Hetey L, Kudrin VS, Shemanow AW. Presynaptic dopamine and serotonin receptors modulating tyrosine hydroxylase activity in synaptosomes of the nucleus accumbens of rats. Eur J Pharmacol. 1985;113:1-10.
20. 2-Autoreceptor-mediated modulation of tyrosine hydroxylase activity in noradrenergic regions of the rat brain in vivo. Naunyn-Schmied. Arch Pharmacol. 1992;345:653-660.
21. El Miestikawy S, Hamon M. Is dopamine-induced inhibition of adenylate cyclase involved in the autoreceptor-mediated negative control of tyrosine hydroxylase in striatal dopaminergic terminals? J Neurochem. 1986;47:1425-1433.
22. + in PC12 cells in culture. Mol Pharmacol. 1984;26:141-147.
23. β) receptor-mediated inhibition of tyrosine hydroxylase activity in the striatum of rat. Neuropharm. 1991;30:1047-1051.
24. Olianas MC, Onali P. Activation of adrenosine A1 receptor by N6-®-phenyllisopropyladenosine (R-PIA) inhibits forskolin-stimulated tyrosine hydroxylase activity in rat striated synaptosomes. Life Sci. 1990;46:591-598.
25. Doods HN, Wienon W, Entzenoth M, et al. Pharmacological characterization of the selective nonpeptide YY1 receptor antagonist BIBP 3226. J Pharm Exp Ther. 1995;275:136-142.
26. Westfall TC. Prejunctional effects of neuropeptide Y and its role as a cotransmitter. Handbook of Experimental Pharmacology. 2004;162:138-183.
27. Donoso MV, Delpiano AM, Huidobro-Toro JP. Modulator role of neuropeptide Y in human vascular sympathetic neuroeffector junctions. In: Zukowaska Z, Feurstein GZ, eds. NPY Family of Peptides in Neurobilogy, Cardiovascsular and Metabolic Disorders: From Genes to Therapy. 2006:65-76.
28. Edvinsson L. Neuropeptide Y and the cerebral circulation. In: Zukowaska Z, Feurstein GZ, eds. NPY Family of Peptides in Neurobilogy, Cardiovascsular and Metabolic Disorders: From Genes to Therapy. 2006:105-112.
29. McCullough LA, Egan TM, Westfall TC. Neuropeptide Y receptors involved in calcium channel regulation in PC12 cells. Regulat Peptides. 1998b;75-76:101-107.
30. Wahlestedt C, Yaniahara N, Hakansson R. Evidence for different pre and post-junctional receptors for neuropeptide Y and related peptides. Regul Peptides. 1986;13:307-318.
31. McAuley M, Westfall TC. Possible location and function of neuropeptide Y receptor subtypes in the rat mesenteric arterial bed. J Pharm Exp Ther. 1992;261:863-868.
32. Grundemar L, Jonas SE, Morns N, et al. Characterization of vascular neuropeptide Y receptors. Br J Pharmacol. 1992;105:45-50.
33. Doods HN, Krause J. Different NPY receptors subtypes in rat and rabbit vas deferens. Eur J Pharmacol. 1991;204:101-105.
34. 2+ channels in acutely isolated neurons from the rat acculate nucleus. J Neurophysiol. 1999;81:1391-1403.
35. 2 receptors: evidence from benextramine protection studies. J Pharm Exp Ther. 1993;265:172-177.